Reimbursement decisions almost always concern pharmaceuticals. But other types of healthcare interventions should also be critically assessed. Or is that not so
Frederick Thielen Current Challenges in Health Technology Assessment: Assessing costs and cost-effectiveness of novel treatments in haemato-oncology December